Bond.az White LogoBond.az Black Logo

Starbucks SWOT analysis: stock navigates turnaround

Starbucks SWOT analysis: a deep dive into the coffee giant's turnaround strategy, financial targets, competitive threats, and valuation risks.

Chloe Hall
ByChloe Hall- Senior Editor
|
0

Starbucks Corporation (NASDAQ:SBUX) is at a critical juncture as it executes an ambitious turnaround strategy through fiscal 2028.

The "Back to Starbucks" initiative shows early traction. U.S. and international comparable sales beat expectations in Q1 FY2026.

Improved financial transparency and clear guidance support investor confidence. EPS target for 2028 is $3.35-$4.00, implying 27% CAGR.

Franchising China operations reduces risk. A $2 billion cost savings program and digital transformation are key drivers.

Competition intensifies, with chains like Dutch Bros gaining share. The stock trades at a premium P/E of 79.58.

Bullish analysts see upside to $150; bearish scenarios point to $78. Low institutional ownership leaves room for upward momentum.

More News
2026-05-26 01:03
|
269

Lennar SWOT analysis: homebuilder stock under pressure

Lennar SWOT analysis: margin pressure, leadership changes, and strategic transformation. Learn the impact on the stock.

0
2026-05-26 00:32
|
816

Group 1 Automotive SWOT: UK Headwinds Impact Stock

Group 1 Automotive SWOT analysis: UK market headwinds, US growth opportunities, and GPI stock valuation.

0
2026-05-26 00:30
|
232

Lumentum: Optical Stock Poised for AI Data Center Growth

Lumentum Holdings is poised for growth with AI data center demand. Exclusive NVIDIA partnership and 50%+ market share in optical components.

0
2026-05-26 00:04
|
842

Lowe's SWOT analysis: stock faces rate headwinds

Lowe's SWOT analysis: interest rates, aging housing stock, and competitive landscape impacting the stock.

0
2026-05-25 23:31
|
760

Equinix SWOT analysis: data center growth amid AI demand

Equinix SWOT analysis: Data center expansion strategy, financials, risks, and opportunities in the AI-driven market.

0
2026-05-25 23:00
|
518

Benitec Biopharma gene therapy stock shows clinical promise

Benitec Biopharma gene therapy stock shows clinical promise. BB-301 achieves 100% response rate in OPMD. Analysis on Bond.az.

0
2026-05-25 22:33
|
434

Rollins SWOT Analysis: Pest Stock at Premium Valuation

Rollins Inc. SWOT analysis: pest control stock navigates premium valuation, growth prospects, and risks.

0
2026-05-25 22:30
|
757

Invesco SWOT: Growth vs Costs

Invesco SWOT analysis: strong revenue growth but rising costs. Positioned with ETF and QQQ strategies.

0
2026-05-25 22:00
|
932

Visteon SWOT Analysis: Stock Eyes Recovery

Visteon Corporation SWOT analysis: automotive electronics supplier's recovery potential in 2026. Key partnerships with Toyota, Honda, NVIDIA, Qualcomm and financial targets.

0
2026-05-25 21:32
|
864

MSCI SWOT Analysis: Stock Shows Strong Momentum

MSCI SWOT analysis: Strong Index subscription momentum, ABF outperformance, and growth opportunities in AI and private assets. Barclays maintains Overweight rating with $700 price target.

0
2026-05-25 21:30
|
268

NXP Semiconductors SWOT analysis

NXP Semiconductors SWOT analysis: strengths, weaknesses, opportunities, and threats. Position in the semiconductor industry and future prospects.

0
2026-05-25 21:01
|
599

W.R. Berkley stock faces growth concerns

W.R. Berkley stock faces premium growth slowdown and reserve pressures. Bond.az analysis provides insights for informed investment decisions.

0
...